Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04875975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04875975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Terminated
Start date
September 27, 2021
Completion date
April 26, 2024
Enrollment
12 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

leucine-rich glioma inactivated 1 autoimmune encephalitis